| FATE SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Fate Therapeutics, Inc. (NASDAQ: FATE) and Encourages Long-Term FATE Investors to Contact the Firm | 06/13 08:00 | prnewswire.com |
| Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) | 06/04 16:01 | globenewswire.com |
| Fate Therapeutics to Present at 2024 Jefferies Global Healthcare Conference | 05/29 16:01 | globenewswire.com |
| Russell Investments Group Ltd. Acquires 59,267 Shares of Fate Therapeutics, Inc. (NASDAQ:FATE) | 05/20 05:04 | https://www.defenseworld.net |
| Fate Therapeutics, Inc. Expected to Post Q2 2024 Earnings of ($0.40) Per Share (NASDAQ:FATE) | 05/20 01:38 | https://www.defenseworld.net |
| Fate Therapeutics, Inc. (FATE) Q1 2024 Earnings Call Transcript | 05/11 18:12 | seekingalpha.com |
| Fate Therapeutics (FATE) Reports Q1 Loss, Tops Revenue Estimates | 05/09 18:26 | zacks.com |
| Fate Therapeutics Reports First Quarter 2024 Financial Results and Business Updates | 05/09 16:01 | globenewswire.com |
| Fate Therapeutics Announces First Lupus Patient Treated in Phase 1 Autoimmunity Study of Off-the-shelf FT819 CAR T-cell Program | 05/09 08:30 | globenewswire.com |
| Fate Therapeutics Announces Presentation of FT522 Preclinical Data for Autoimmune Diseases in Late-breaking Abstract at ASGCT Annual Meeting | 05/03 16:30 | globenewswire.com |